论文部分内容阅读
乐伐替尼(lenvatinib,1,别名E7080),化学名为4-[3-氯-4-(环丙基氨基羰基)氨基苯氧基]-7-甲氧基-6-喹啉甲酰胺,分子式C21H19Cl N4O4,分子量522.96,CAS登记号417716-92-8。该药是由日本卫材(Eisai)公司开发的一种口服多靶点受体酪氨酸激酶(RTKs)抑制剂,研究表明,除抑制促血管生成和致癌信号通路相关RTK外,还
Lenvatinib (1, alias E7080) with chemical name 4- [3-chloro-4- (cyclopropylaminocarbonyl) aminophenoxy] -7-methoxy-6-quinolinecarboxamide , Formula C21H19ClN4O4, molecular weight 522.96, CAS Registry Number 417716-92-8. The drug is an oral multi-target receptor tyrosine kinase (RTKs) inhibitor developed by Japan’s Eisai Corporation. Studies have shown that in addition to inhibiting RTKs associated with pro-angiogenic and oncogenic signaling pathways